Clal Biotechnology Industries - Portfolio progress continues
Clal Biotechnology Industries’ (CBI) portfolio of investments continues to demonstrate forward-looking business development and clinical progress. Notably, MediWound announced in May that it is now in discussions with multiple third parties interested in a strategic transaction. Still, the nature of these approaches remains unclear. Also, BioCanCell announced a $23m private equity investment and plans to use the proceeds to initiate two studies for its lead programme. Lastly, Neon filed a prospectus with the SEC detailing an IPO expected to raise ~$100m on NASDAQ.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.